GlassScriptPhysician profile
Nishant Patel
NPI 1336373232
$5,335.80
in general payments reported to CMS, 2019-2025
18 companies · $627 in 2025
The $627 reported for 2025 was more than what 77% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,809 · 2020: $273 · 2021: $64.63 · 2022: $152 · 2023: $1,708 · 2024: $702 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,023 · Education: $14.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,022.98 |
| Education | $14.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,668.90 | 2023-2024 | |
| Qol Medical, LLC | $1,574.64 | 2019 | |
| Abbvie INC. | $864.30 | 2019-2025 | |
| Ethicon US, LLC | $170.54 | 2025 | Vistaseal |
| Medtronic, INC. | $150.41 | 2023 | Prodigi |
| Genzyme Corporation | $143.49 | 2023-2025 | |
| Mirum Pharmaceuticals, INC. | $139.15 | 2025 | Livmarli |
| Abiomed | $138.55 | 2020 | |
| Coloplast Corp | $119.16 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $116.60 | 2022-2023 | Smoflipid |
| Takeda Pharmaceuticals U.S.A., INC. | $43.45 | 2022-2024 | Eohilia |
| Rhythm Pharmaceuticals, INC. | $42.27 | 2022-2023 | Imcivree |
| Terumo Medical Corporation | $39.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $36.85 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $34.07 | 2023-2024 | Dupixent |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $23.42 | 2023 | Wavewriter Alpha Prime 16 |
| Aimmune Therapeutics, INC. | $15.76 | 2025 | Zenpep |
| Janssen Biotech, INC. | $14.61 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishant Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.